Shaikha Alqahtani
Overview
Explore the profile of Shaikha Alqahtani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
9
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McCall D, Alqahtani S, Budak M, Sheikh I, Fan A, Ramakrishnan R, et al.
Cancers (Basel)
. 2024 Nov;
16(22).
PMID: 39594839
Cladribine-based combination chemotherapy has demonstrated promising efficacy in patients with relapsed/refractory adult acute myeloid leukemia (AML), prompting its increased utilization in the frontline; in pediatrics, it has been typically reserved...
2.
Alqahtani S, DiValerio Gibbs K, Montanez N, Krause K, van Ommen C, Srivaths L
Pediatr Blood Cancer
. 2024 Jun;
71(9):e31131.
PMID: 38899913
Adolescent venous thromboembolism (VTE) has unique challenges in management, complications, and compliance to anticoagulants. Direct oral anticoagulants (DOACs) have been approved for pediatric VTE management, with an increasing use especially...
3.
Alqahtani S, Ramakrishnan R, E S, Wang S, Nunez C, McCall D, et al.
Pediatr Blood Cancer
. 2024 Jun;
71(8):e31123.
PMID: 38837565
No abstract available.
4.
Hummel L, Ameri M, Alqahtani S, Sadighi Z, Al-Zubidi N
Curr Oncol
. 2024 May;
31(5):2644-2649.
PMID: 38785480
MEK inhibitors (MEKi) represent innovative and promising treatments for managing manifestations of neurofibromatosis type 1 (NF1). To mitigate potential ophthalmic side effects, such as MEKi-associated retinopathy (MEKAR), patients undergoing MEKi...
5.
Sheikh I, Alqahtani S, Yin C, McCall D, Cuglievan B, Ragoonanan D, et al.
Pediatr Blood Cancer
. 2024 Jan;
71(4):e30898.
PMID: 38291730
No abstract available.
6.
Munir F, Hardit V, Sheikh I, Alqahtani S, He J, Cuglievan B, et al.
Int J Mol Sci
. 2023 Jun;
24(12).
PMID: 37373245
Hodgkin lymphoma, a hematological malignancy of lymphoid origin that typically arises from germinal-center B cells, has an excellent overall prognosis. However, the treatment of patients who relapse or develop resistant...
7.
Sheikh I, Alqahtani S, Ragoonanan D, Tewari P, Petropoulos D, Mahadeo K, et al.
Int J Mol Sci
. 2022 Aug;
23(15).
PMID: 35955881
Non-relapse mortality due to GVHD and infections represents a major source of morbidity and mortality in pediatric HSCT recipients. Post-transplant cyclophosphamide (PTCy) has emerged as an effective and safe GVHD...